EG 1211X
Alternative Names: EG-1211XLatest Information Update: 03 Nov 2024
Price :
$50 *
At a glance
- Originator EirGenix
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 29 Aug 2024 Preclinical trials in Cancer in Taiwan (Parenteral), before August 2024 (EirGenix pipeline, August 2024)